Suppr超能文献

脂康饮配方通过调节小鼠肠道微生物群-胆汁酸轴减轻高脂饮食诱导的代谢紊乱。

Zhi-Kang-Yin formula attenuates high-fat diet-induced metabolic disorders through modulating gut microbiota-bile acids axis in mice.

作者信息

Li Yifan, Wang Hao, He Xiaofang, Zhu Weize, Bao Yiyang, Gao Xinxin, Huang Wenjin, Ge Xinyu, Wei Wenjing, Zhang Huan, Sheng Lili, Zhang Tao, Li Houkai

机构信息

School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.

Department of Liver Disease, The First Hospital of Hunan University of Chinese Medicine, Hunan, 410007, China.

出版信息

Chin Med. 2024 Oct 18;19(1):145. doi: 10.1186/s13020-024-01021-w.

Abstract

BACKGROUND

Metabolic disorders have become one of the global medical problems. Due to the complexity of its pathogenesis, there is still no effective treatment. Bile acids (BAs) and gut microbiota (GM) have been proved to be closely related to host metabolism, which could be important targets for metabolic disorders. Zhi-Kang-Yin (ZKY) is a traditional Chinese medicine (TCM) formula developed by the research team according to theory of TCM and has been shown to improve metabolism in clinic. However, the underlying mechanisms are unclear.

AIM OF THE STUDY

This study aimed to investigate the potential mechanisms of the beneficial effect of ZKY on metabolism.

METHODS

High-fat diet (HFD)-fed mice were treated with and without ZKY. The glucose and lipid metabolism-related indexes were measured. BA profile, GM composition and hepatic transcriptome were then investigated to analyze the changes of BAs, GM, and hepatic gene expression. Moreover, the relationship between GM and BAs was identified with functional gene quantification and ex vivo fermentation experiment.

RESULTS

ZKY reduced weight gain and lipid levels in both liver and serum, attenuated hepatic steatosis and improved glucose tolerance in HFD-fed mice. BA profile detection showed that ZKY changed the composition of BAs and increased the proportion of unconjugated BAs and non-12-OH BAs. Hepatic transcriptomic analysis revealed fatty acid metabolism and BA biosynthesis related pathways were regulated. In addition, ZKY significantly changed the structure of GM and upregulated the gene copy number of bacterial bile salt hydrolase. Meanwhile, ZKY directly promoted the growth of Bifidobacterium, which is a well-known bile salt hydrolase-producing genus. The ex vivo co-culture experiment with gut microbiota and BAs demonstrated that the changes of BAs profile in ZKY group were mediated by ZKY-shifted GM, which led to increased expression of genes associated with fatty acid degradation in the liver.

CONCLUSION

Our study indicated that the effect of ZKY on improving metabolism is associated with the modulation of GM-BAs axis, especially, by upregulating the abundance of bile salt hydrolase-expression bacteria and increasing the levels of unconjugated BAs. This study indicates that GM-BAs axis might be an important pathway for improving metabolic disorders by ZKY.

摘要

背景

代谢紊乱已成为全球性医学问题之一。由于其发病机制复杂,目前仍无有效治疗方法。胆汁酸(BAs)和肠道微生物群(GM)已被证明与宿主代谢密切相关,可能是代谢紊乱的重要靶点。脂康饮(ZKY)是研究团队依据中医理论研制的中药方剂,临床研究表明其具有改善代谢的作用。然而,其潜在机制尚不清楚。

研究目的

本研究旨在探讨ZKY改善代谢的潜在机制。

方法

将高脂饮食(HFD)喂养的小鼠分为ZKY给药组和不给药组,检测其糖脂代谢相关指标。随后分析胆汁酸谱、肠道微生物群组成及肝脏转录组,以分析胆汁酸、肠道微生物群和肝脏基因表达的变化。此外,通过功能基因定量和体外发酵实验确定肠道微生物群与胆汁酸之间的关系。

结果

ZKY降低了HFD喂养小鼠的体重增加及肝脏和血清中的脂质水平,减轻了肝脏脂肪变性,改善了葡萄糖耐量。胆汁酸谱检测显示,ZKY改变了胆汁酸的组成,增加了未结合胆汁酸和非12-羟基胆汁酸的比例。肝脏转录组分析表明,脂肪酸代谢和胆汁酸生物合成相关途径受到调控。此外,ZKY显著改变了肠道微生物群的结构,上调了细菌胆盐水解酶的基因拷贝数。同时,ZKY直接促进了双歧杆菌的生长,双歧杆菌是一种著名的产胆盐水解酶属。肠道微生物群与胆汁酸的体外共培养实验表明,ZKY组胆汁酸谱的变化是由ZKY改变的肠道微生物群介导的,这导致肝脏中脂肪酸降解相关基因的表达增加。

结论

我们的研究表明,ZKY改善代谢的作用与调节肠道微生物群-胆汁酸轴有关,特别是通过上调胆盐水解酶表达细菌的丰度和增加未结合胆汁酸的水平。本研究表明,肠道微生物群-胆汁酸轴可能是ZKY改善代谢紊乱的重要途径。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b54/11490013/92631897b8ac/13020_2024_1021_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验